common.study.topics.clinical

HER2-Low Breast Cancer

common.study.values.description

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: - Cannot be removed by an operation - Has spread to other parts of the body

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Trastuzumab deruxtecan (DS-8201a)

DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously

Drug - Capecitabine

Administered according to label, as one option for Physician's Choice (determined before randomization)

Drug - Eribulin

Administered according to label, as one option for Physician's Choice (determined before randomization)

Drug - Gemcitabine

Administered according to label, as one option for Physician's Choice (determined before randomization)

Drug - Paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization)

Drug - Nab-paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization)

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

common.study.values.clinical-trial-id

NCT03734029

participant.views.study.view.id

en5Yld